N30 Pharmaceutical appoints Jon Congleton CEO
This article was originally published in Scrip
Boulder, Colorado-based N30 Pharmaceuticals, a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, has named Jon Congleton president and CEO. Mr Congleton will also join the company's board of directors. He joins the firm from Teva Pharmaceuticals, where over 18 years he held positions in general management and global strategic marketing, including senior vice-president of Teva's Central Nervous System Global Franchise, senior VP of the Global Medicines Group, and general manager of Teva Neuroscience.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.